Clinical Trial: Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II

U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07131722) titled 'Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II' on July 01.

Brief Summary: The goal of this clinical trial is to learn if Trineumin(Code name:PRG-N-01) works to treat Neurofibromatosis Type II(NF2) in adults. It will also learn about the safety and tolerability and toxicity of PRG-N-01. The main questions it aims to answer are:

* What dose was determined as the Maximum Tolerated Dose (MTD) of Trineumin?

* What dose was explored as the optimal effective dose of Trineumin based on radiographic response?

* Does Trineumin reduce tumor size or improve participan...